Small Molecule Inhibitors of EZH2: the Emerging Translational Landscape

References

• Margueron R , ReinbergD . The polycomb complex PRC2 and its mark in life . Nature469 ( 7330 ), 343 – 349 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Yamaguchi H , HungMC . Regulation and role of EZH2 in Cancer . Cancer Res. Treat.46 ( 3 ), 209 – 222 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hock H . A complex Polycomb issue: the two faces of EZH2 in cancer . Genes Dev.26 ( 8 ), 751 – 755 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lee W , TeckieS , WiesnerTet al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors . Nat. Genet.46 ( 11 ), 1227 – 1232 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Morin RD , JohnsonNA , SeversonTMet al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin . Nat. Genet.42 ( 2 ), 181 – 185 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Bodor C , O’RiainC , WrenchDet al. EZH2 Y641 mutations in follicular lymphoma . Leukemia25 ( 4 ), 726 – 729 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Sneeringer C , ScottMP , KuntzKWet al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas . Proc. Natl Acad. Sci. USA107 ( 49 ), 20980 – 20985 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Yap DB , ChuJ , BergTet al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation . Blood117 ( 8 ), 2451 – 2459 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Swalm BM , KnutsonSK , WarholicNMet al. Reaction coupling between wild-type and disease-associated mutant EZH2 . ACS Chem. Biol.9 ( 11 ), 2459 – 2464 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Bradley WD , AroraS , BusbyJet al. EZH2 inhibitor efficacy in non-Hodgkin’s lymphoma does not require suppression of H3K27 monomethylation . Chem. Biol.21 ( 11 ), 1463 – 1475 ( 2014 ).
   PubMedGoogle Scholar
• Knutson SK , KawanoS , MinoshimaYet al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma . Mol. Cancer Ther.13 ( 4 ), 842 – 854 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Knutson SK , WigleTJ , WarholicNMet al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells . Nat. Chem. Biol.8 ( 11 ), 890 – 896 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Beguelin W , PopovicR , TeaterMet al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation . Cancer Cell23 ( 5 ), 677 – 692 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• McCabe MT , OttHM , GanjiGet al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations . Nature492 ( 7427 ), 108 – 112 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Verma SK , TianX , LaFranceLVet al. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2 . ACS Med. Chem. Lett.3 ( 12 ), 1091 – 1096 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Qi W , ChanH , TengLet al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation . Proc. Natl Acad. Sci. USA109 ( 52 ), 21360 – 21365 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Konze KD , MaA , LiFet al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1 . ACS. Chem. Biol.8 ( 6 ), 1324 – 1334 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Knutson SK , WarholicNM1 , JohnstonLDet al. Synergistic anti-tumor activity of EZH2 inhibitors and glucocorticoid receptor agonists in models of germinal center non-Hodgkin lymphomas . PLoS ONE9 ( 12 ), e111840 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lee RS , StewartC , CarterSLet al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers . J. Clin. Invest.122 ( 8 ), 2983 – 2988 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Wilson BG , WangX , ShenXet al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation . Cancer Cell18 ( 4 ), 316 – 328 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Knutson SK , WarholicNM , WigleTJet al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 . Proc. Natl Acad. Sci. USA110 ( 19 ), 7922 – 7927 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Agaimy A . The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity . Adv. Anat. Pathol.21 ( 6 ), 394 – 410 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ribrag V , SoriaJC , ReydermanLet al. 6LBA Phase 1 first-in-human study of the enhancer of zeste-homolog 2 (EZH2) histone methyl transferase inhibitor E7438 as a single agent in patients with advanced solid tumors or B cell lymphoma . Eur. J. Cancer50 ( 2014 ), 197 ( 2014 ).
   Google Scholar
• Zhou Z , GaoJ , PopovicRet al. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma (DLBCL) independent of cell of origin and EZH2 codon 641 mutation . Leuk. Lymphoma1 – 7 ( 2015 ) ( Epub Ahead of Print ).
   Web of Science ®Google Scholar
• Scott DW , GascoyneRD . The tumour microenvironment in B cell lymphomas . Nat. Rev. Cancer14 ( 8 ), 517 – 534 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Arvey A , van der VeekenJ , SamsteinRMet al. Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells . Nat. Immunol.15 ( 6 ), 580 – 587 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Keilhack H , KawanoS , KnutsonSKet al. Preclinical evaluation of EZH2 inhibitors in models of Human Synovial Sarcoma . Presented at : Connective Tissue Oncology SocietyBerlin, Germany , 15–18 October 2014 ( Poster 283 ).
   Google Scholar